These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 21385902

  • 1. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.
    Zhang D, He D, Xue Y, Wang R, Wu K, Xie H, Zeng J, Wang X, Zhau HE, Chung LW, Chang LS, Li L.
    Cancer Res; 2011 Mar 15; 71(6):2193-202. PubMed ID: 21385902
    [Abstract] [Full Text] [Related]

  • 2. PrLZ expression is associated with the progression of prostate cancer LNCaP cells.
    Li L, Zhang D, Zhang L, Zhu G, Sun Y, Wu K, Wang X, He D.
    Mol Carcinog; 2009 May 15; 48(5):432-40. PubMed ID: 18800346
    [Abstract] [Full Text] [Related]

  • 3. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
    Li L, Xie H, Liang L, Gao Y, Zhang D, Fang L, Lee SO, Luo J, Chen X, Wang X, Chang LS, Yeh S, Wang Y, He D, Chang C.
    Carcinogenesis; 2013 Feb 15; 34(2):257-67. PubMed ID: 23104178
    [Abstract] [Full Text] [Related]

  • 4. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt.
    Miyazaki T, Bub JD, Iwamoto Y.
    Biochim Biophys Acta; 2008 Oct 15; 1782(10):593-604. PubMed ID: 18718531
    [Abstract] [Full Text] [Related]

  • 5. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J, Liu W, Fan YZ, He DL, Li L.
    Theranostics; 2018 Oct 15; 8(1):109-123. PubMed ID: 29290796
    [Abstract] [Full Text] [Related]

  • 6. PC-1/PrLZ contributes to malignant progression in prostate cancer.
    Zhang H, Wang J, Pang B, Liang RX, Li S, Huang PT, Wang R, Chung LW, Zhau HE, Huang C, Zhou JG.
    Cancer Res; 2007 Sep 15; 67(18):8906-13. PubMed ID: 17875733
    [Abstract] [Full Text] [Related]

  • 7. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
    Yang CC, Lin HP, Chen CS, Yang YT, Tseng PH, Rangnekar VM, Chen CS.
    J Biol Chem; 2003 Jul 11; 278(28):25872-8. PubMed ID: 12738789
    [Abstract] [Full Text] [Related]

  • 8. [Biological implications of the inhibition of survivin by RNA interference in human androgen-independent prostate carcinoma with highly metastatic potential].
    Zhu X, Ning JY, You JF, Wang JL, Cui XL, Fang WG, Zheng J.
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep 11; 35(9):549-54. PubMed ID: 17134550
    [Abstract] [Full Text] [Related]

  • 9. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M.
    Cancer Res; 2005 Dec 01; 65(23):11083-93. PubMed ID: 16322258
    [Abstract] [Full Text] [Related]

  • 10. Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis.
    Chen W, Liu Y, Chen H, Ning H, Ding K.
    Int J Oncol; 2017 Aug 01; 51(2):435-444. PubMed ID: 28627667
    [Abstract] [Full Text] [Related]

  • 11. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO, Dutt SS, Nadiminty N, Pinder E, Liao H, Gao AC.
    Prostate; 2007 Sep 01; 67(12):1293-300. PubMed ID: 17626246
    [Abstract] [Full Text] [Related]

  • 12. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo.
    Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ.
    Int J Mol Med; 1998 Jun 01; 1(6):953-9. PubMed ID: 9852630
    [Abstract] [Full Text] [Related]

  • 13. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.
    Prostate; 2004 Feb 15; 58(3):259-68. PubMed ID: 14743465
    [Abstract] [Full Text] [Related]

  • 14. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.
    Zhou J, Ning Z, Wang B, Yun EJ, Zhang T, Pong RC, Fazli L, Gleave M, Zeng J, Fan J, Wang X, Li L, Hsieh JT, He D, Wu K.
    Cell Death Dis; 2015 Oct 29; 6(10):e1955. PubMed ID: 26512963
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R.
    Cancer Res; 1995 Oct 01; 55(19):4438-45. PubMed ID: 7671257
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.
    Lee SO, Lou W, Johnson CS, Trump DL, Gao AC.
    Prostate; 2004 Aug 01; 60(3):178-86. PubMed ID: 15176047
    [Abstract] [Full Text] [Related]

  • 17. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A.
    J Cell Physiol; 2007 May 01; 211(2):533-43. PubMed ID: 17192846
    [Abstract] [Full Text] [Related]

  • 18. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
    Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW.
    Clin Cancer Res; 2003 Jul 01; 9(7):2416-25. PubMed ID: 12855613
    [Abstract] [Full Text] [Related]

  • 19. Different effects of corticotropin-releasing factor and urocortin 2 on apoptosis of prostate cancer cells in vitro.
    Jin L, Zhang Q, Guo R, Wang L, Wang J, Wan R, Zhang R, Xu Y, Li S.
    J Mol Endocrinol; 2011 Oct 01; 47(2):219-27. PubMed ID: 21765100
    [Abstract] [Full Text] [Related]

  • 20. Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins.
    Wang R, He H, Sun X, Xu J, Marshall FF, Zhau H, Chung LW, Fu H, He D.
    Biochem Biophys Res Commun; 2009 Nov 20; 389(3):455-60. PubMed ID: 19732746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.